Press coverage about Nevro (NYSE:NVRO) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 47.9458649232043 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Market Cap to Track – Nevro Corp. (NYSE:NVRO) (nasdaqjournal.com)
- PPO Below Signal on Shares of Nevro Corp (NVRO) (fisherbusinessnews.com)
- Hot Stock’s Highlights – Nevro Corp (NYSE: NVRO) (stockspen.com)
- After Yesterday’s Decline of 1.31%, Nevro Corp Offers Investors Better Value (mysmartrend.com)
- Nevro Corp. (NVRO)- Healthcare stock Analysis Review (nasdaqfortune.com)
NVRO has been the topic of a number of recent analyst reports. ValuEngine downgraded shares of Nevro from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded shares of Nevro from a “hold” rating to a “sell” rating in a report on Wednesday, February 28th. Goldman Sachs initiated coverage on shares of Nevro in a report on Wednesday, April 4th. They set a “neutral” rating and a $83.00 price target on the stock. JMP Securities reaffirmed an “overweight” rating and set a $105.00 price target (down previously from $120.00) on shares of Nevro in a report on Tuesday, May 8th. Finally, Wells Fargo downgraded shares of Nevro from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 8th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $98.78.
Nevro opened at $72.64 on Tuesday, according to MarketBeat. The company has a current ratio of 7.99, a quick ratio of 6.17 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $2.19 billion, a P/E ratio of -58.11 and a beta of -0.52. Nevro has a 12-month low of $65.00 and a 12-month high of $94.34.
Nevro (NYSE:NVRO) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $97.96 million during the quarter, compared to analysts’ expectations of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.34) EPS. equities research analysts predict that Nevro will post -1.2 earnings per share for the current year.
In related news, Director Wilfred E. Jaeger sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $80.48, for a total value of $804,800.00. Following the transaction, the director now owns 1,518 shares of the company’s stock, valued at $122,168.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Wilfred E. Jaeger sold 14,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $83.28, for a total transaction of $1,204,062.24. Following the completion of the transaction, the director now directly owns 1,518 shares in the company, valued at approximately $126,419.04. The disclosure for this sale can be found here. In the last three months, insiders sold 241,116 shares of company stock worth $19,446,802. 6.90% of the stock is currently owned by insiders.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.